Oragenics Inc. (OGEN): Price and Financial Metrics
OGEN Price/Volume Stats
| Current price | $1.03 | 52-week high | $7.74 |
| Prev. close | $1.06 | 52-week low | $1.01 |
| Day low | $1.01 | Volume | 43,800 |
| Day high | $1.08 | Avg. volume | 80,738 |
| 50-day MA | $1.64 | Dividend yield | N/A |
| 200-day MA | $3.29 | Market Cap | 4.62M |
OGEN Stock Price Chart Interactive Chart >
Oragenics Inc. (OGEN) Company Bio
Oragenics, Inc. is a biotechnology research and development company seeking to commercialize technologies based on different strains of bacterias. The Company's technologies include a replacement therapy for tooth cavity protection and a new broad-spectrum antibiotic.
Latest OGEN News From Around the Web
Below are the latest news stories about ORAGENICS INC that investors may wish to consider to help them evaluate OGEN as an investment opportunity.
Oragenics Issues Update to ShareholdersTAMPA, Fla., November 02, 2023--Oragenics, Inc. (NYSE American: OGEN): |
Oragenics Announces Appointment of Bruce Cassidy and John Gandolfo to Board of DirectorsTAMPA, Fla., October 18, 2023--Oragenics, Inc. (NYSE American: OGEN) ("Oragenics" or the "Company") announced the appointments of Bruce Cassidy and John Gandolfo to the Board of Directors effective October 4, 2023. |
Oragenics to Acquire Odyssey Health’s Neurological Drug Technology Pipeline Including Concussion Drug CandidateTAMPA, Fla. & LAS VEGAS, October 05, 2023--Oragenics, Inc. (NYSE American: OGEN) ("Oragenics" or the "Company") and Odyssey Health, Inc. (OTCQB: ODYY) ("Odyssey") announce the signing of a definitive agreement under which Oragenics will acquire Odyssey’s assets related to its proprietary neurological drug therapies and technologies. The assets include drug candidates for treating mild traumatic brain injury (mTBI), also known as concussion, and for treating Niemann Pick Disease Type C (NPC), as |
Oragenics Enters into Agreement with Lantern Bioworks for Replacement-Therapy AssetsTAMPA, Fla., September 29, 2023--Oragenics, Inc. (NYSE American: OGEN) ("Oragenics" or the "Company") and Lantern Bioworks announce a groundbreaking partnership, marked by the formalization of a materials transfer agreement. This milestone follows rigorous testing and validation of Oragenics’ biological samples, which are poised to potentially revolutionize dental caries prevention by replacing harmful bacterial strains with non-pathogenic counterparts. |
Oragenics, Inc. Announces Private PlacementTAMPA, Fla., August 07, 2023--Oragenics, Inc. (NYSE American: OGEN) ("Oragenics" or the "Company"), biotech company dedicated to fighting infectious diseases including coronaviruses, today announced it has entered into definitive agreements with two healthcare-focused investors, in which the Company issued in a private placement (the "Private Placement Offering"), an aggregate of (i) 404,728 shares of the Company’s common stock, $0.001 par value (the "Common Stock"), and (ii) 404,728 shares of S |
OGEN Price Returns
| 1-mo | N/A |
| 3-mo | -77.85% |
| 6-mo | -71.70% |
| 1-year | -63.21% |
| 3-year | -97.87% |
| 5-year | -96.76% |
| YTD | -81.69% |
| 2023 | -10.78% |
| 2022 | -76.43% |
| 2021 | -0.67% |
| 2020 | -14.15% |
| 2019 | -39.19% |
Loading social stream, please wait...